Kronos Bio, Inc. – NASDAQ:KRON

Add to watchlist

$0.88

-0.05

-6.38%

Market closed

Open in 3 days

-34.27%

month

-34.27%

quarter

-25.98%

year

Market Cap	56.12M
Enterprise value	27.61M

P/E	-0.53
EV/Sales	N/A
EV/EBITDA	-0.14
Price/Sales	N/A
Price/Book	0.29
PEG ratio	-0.03
EPS	-1.99

Revenue	7.58M
EBITDA	-110.21M
Income	-116.39M
Revenue Q/Q	106.38%
Revenue Y/Y	521.37%

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	-1452.7%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Kronos Bio Stock Forecast

M Q Y

Last Year

Potential upside: 13.63%

Analysts Price target
Financials & Ratios estimates

Kronos Bio, Inc. (NASDAQ:KRON): Profit margin
Jun 2023	1.86M	-29.74M	-1595.55%
Sep 2023	917K	-31.37M	-3421.37%
Dec 2023	2.28M	-25.32M	-1107.61%
Mar 2024	2.52M	-29.95M	-1188.81%

Kronos Bio, Inc. (NASDAQ:KRON): Debt to assets
Jun 2023	260615000	57.27M	21.98%
Sep 2023	237993000	59.37M	24.95%
Dec 2023	213279000	54.20M	25.41%
Mar 2024	182979000	46.01M	25.15%

Kronos Bio, Inc. (NASDAQ:KRON): Cash Flow
Jun 2023	-25.02M	5.37M	376K
Sep 2023	-22.58M	35.78M	0
Dec 2023	-25.02M	31.56M	191K
Mar 2024	-23.89M	5.77M	0

Kronos Bio alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Kronos Bio, Inc. (NASDAQ:KRON): Employee count
Aug 2023	94
Sep 2023	104
Oct 2023	104
Nov 2023	104
Dec 2023	99
Jan 2024	99
Feb 2024	99
Apr 2024	62
May 2024	62
Jun 2024	61
Jul 2024	61

Kronos Bio
Hedge Funds Holdings Q3 2022

59.68% -3.91%

of KRON is owned by hedge funds

86 -5

hedge funds hold KRON stock

33.49M -2.02M

shares is hold by hedge funds

KRON hedge funds holdings changes

Kronos Bio, Inc. (NASDAQ:KRON): Insider trades (number of shares)
Period	Buy	Sel
Jul 2023	0	27069
Nov 2023	1731056	0
Dec 2023	0	27399
Jan 2024	0	30051
Feb 2024	0	31509
Jun 2024	3620640	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	28 Jun 2024	BISCHOFBERGER NORBERT W director, officer: PRESIDENT & CEO director, officer: PRESIDENT & ..	Common Stock	204,670	$1.25	$255,019
Purchase	27 Jun 2024	BISCHOFBERGER NORBERT W director, officer: PRESIDENT & CEO director, officer: PRESIDENT & ..	Common Stock	410,848	$1.17	$479,049
Purchase	12 Jun 2024	BISCHOFBERGER NORBERT W director, officer: PRESIDENT & CEO director, officer: PRESIDENT & ..	Common Stock	881,913	$1.24	$1,096,218
Purchase	11 Jun 2024	BISCHOFBERGER NORBERT W director, officer: PRESIDENT & CEO director, officer: PRESIDENT & ..	Common Stock	744,308	$1.09	$814,273
Purchase	10 Jun 2024	BISCHOFBERGER NORBERT W director, officer: PRESIDENT & CEO director, officer: PRESIDENT & ..	Common Stock	1,378,901	$0.88	$1,207,917
Sale	21 Feb 2024	OLEK ELIZABETH A officer: SR VP, CLINICAL SCIENCE officer: SR VP, CLINICAL SCIENCE	Common Stock	7,368	$1.05	$7,766
Sale	21 Feb 2024	LIN CHARLES Y officer: SR VP, RESEARCH & DEVELOPMENT officer: SR VP, RESEARCH & DEVE..	Common Stock	12,036	$1.05	$12,686
Sale	21 Feb 2024	FRISBEE ALLISON officer: SR VP, CORP OPERATIONS & LEGAL officer: SR VP, CORP OPERATIONS..	Common Stock	12,105	$1.05	$12,759
Sale	4 Jan 2024	DINSMORE CHRISTOPHER officer: Chief Scientific Officer officer: Chief Scientific Officer	Common Stock	7,366	$1.18	$8,721
Sale	4 Jan 2024	DIMARTINO JORGE officer: Chief Me..	Common Stock	12,009	$1.18	$14,219

Status	Patent	Filling date	Issue date
Grant	Grant Utility: Hydrates of polymorphs of 6-(1H-indazol-6-YL)-N-(4-morpholinophenyl)-2,3-dihydroimidazo[1,2-A]pyraz- in-8-amine bisemsylate as Syk inhibitors Filling date: 10 Aug 2018 Issue date: 12 Jul 2022	10 Aug 2018	12 Jul 2022
Grant	Grant Utility: Crystalline forms of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidaz- o[1,2-a]pyrazin-8-amine as Syk inhibitors Filling date: 20 Feb 2020 Issue date: 24 May 2022	20 Feb 2020	24 May 2022
Application	Application COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CDK9 ACTIVITY Filling date: 15 Sep 2021 Issue date: 6 Jan 2022	15 Sep 2021	6 Jan 2022
Grant	Grant Utility: Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity Filling date: 29 Oct 2019 Issue date: 26 Oct 2021	29 Oct 2019	26 Oct 2021
Application	Application CRYSTALLINE MONOMESYLATE SALT OF 6-(6-AMINOPYRAZIN-2-YL)-N-(4-(4-(OXETAN-3-YL)PIPERAZIN-1-YL)PHENYL)IMIDAZ- O[1,2-a]PYRAZIN-8-AMINE Filling date: 28 Oct 2020 Issue date: 4 Mar 2021	28 Oct 2020	4 Mar 2021
Grant	Grant Utility: Imidazopyridines Syk inhibitors Filling date: 6 Sep 2018 Issue date: 24 Nov 2020	6 Sep 2018	24 Nov 2020
Application	Application Compounds, Compositions, and Methods for Modulating CDK9 Activity Filling date: 29 Oct 2019 Issue date: 30 Apr 2020	29 Oct 2019	30 Apr 2020

Kronos Bio
Executives

Insider	Age	Compensation
Mr. Jorge F. DiMartino M.D., Ph.D. (1963) Chief Medical Officer & Executive Vice President of Clinical Devel.	62	$765,110
Dr. Norbert W. Bischofberger Ph.D. (1956) Pres, Chief Executive Officer & Director	69	$596,370
Dr. Yasir B. Al-Wakeel BCh, BM, MA (1982) Chief Financial Officer & Head of Corporation Devel.	43	$421,260
Mr. David M. Tanen J.D. (1971) Sec. & Director	54	$35,000
Mr. Joshua A. Kazam (1977) Co-Founder & Director	48	$35,000

Kronos Bio
Latest News

Wednesday, 27 November 2024
07:30	Kronos Bio Announces CEO Transition and Reduction in Force	globenewswire.com
Thursday, 14 November 2024
16:02	Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024	globenewswire.com
Wednesday, 13 November 2024
18:36	Kronos Bio downgraded to Neutral from Overweight at Piper Sandler	https://thefly.com
18:31	Kronos Bio, Inc. (KRON) Reports Q3 Loss, Tops Revenue Estimates	zacks.com
Wednesday, 23 October 2024
08:55	Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors	globenewswire.com
Wednesday, 9 October 2024
08:55	Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors	globenewswire.com
Monday, 7 October 2024
08:55	Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren's Disease	globenewswire.com
Wednesday, 25 September 2024
08:55	Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy	globenewswire.com
Monday, 23 September 2024
08:55	Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer	globenewswire.com
Tuesday, 10 September 2024
10:36	After Plunging -5.53% in 4 Weeks, Here's Why the Trend Might Reverse for Kronos Bio (KRON)	zacks.com
Tuesday, 3 September 2024
08:55	Kronos Bio Announces Participation in Medical and Investor Conferences in September	globenewswire.com
Thursday, 22 August 2024
10:36	After Plunging -23.49% in 4 Weeks, Here's Why the Trend Might Reverse for Kronos Bio (KRON)	zacks.com
Tuesday, 6 August 2024
11:05	Kronos Bio, Inc. (KRON) Expected to Beat Earnings Estimates: Should You Buy?	zacks.com
Tuesday, 23 July 2024
16:15	Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer	globenewswire.com
Thursday, 23 May 2024
17:15	Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	globenewswire.com
Wednesday, 22 May 2024
16:30	Kronos Bio to Participate in Three Upcoming Healthcare Conferences and Events	globenewswire.com
Tuesday, 21 May 2024
08:15	Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer	globenewswire.com
Thursday, 16 May 2024
10:36	Down -5.63% in 4 Weeks, Here's Why Kronos Bio (KRON) Looks Ripe for a Turnaround	zacks.com
Thursday, 9 May 2024
18:46	Kronos Bio, Inc. (KRON) Reports Q1 Loss, Tops Revenue Estimates	Zacks Investment Research
Wednesday, 24 April 2024
16:01	Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	GlobeNewsWire
Wednesday, 27 March 2024
13:01	Kronos Bio (KRON) Upgraded to Buy: What Does It Mean for the Stock?	Zacks Investment Research
Tuesday, 5 March 2024
16:44	Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting	GlobeNewsWire
Monday, 4 December 2023
08:00	Kronos Bio Announces Participation in H.C. Wainwright 4th Annual Precision Oncology Virtual Conference	GlobeNewsWire
Monday, 20 November 2023
10:17	Best Penny Stocks To Buy This Week? 4 To Watch Now	PennyStocks
Monday, 13 November 2023
18:47	Kronos Bio, Inc. (KRON) Reports Q3 Loss, Lags Revenue Estimates	Zacks Investment Research
Friday, 27 October 2023
08:00	Kronos Bio To Present Positive Preliminary Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting	GlobeNewsWire
Wednesday, 4 October 2023
16:05	Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13	GlobeNewsWire
Thursday, 1 June 2023
16:05	Kronos Bio Announces Participation in Upcoming Investor Conferences	GlobeNewsWire
Wednesday, 10 May 2023
18:59	Kronos Bio, Inc. (KRON) Reports Q1 Loss, Misses Revenue Estimates	Zacks Investment Research
Monday, 9 January 2023
09:02	5 Hot Penny Stocks To Watch This Week With Big News	PennyStocks

Ideas & Opinions

Seeking Alpha 6 May 2024

Kronos Bio: Underestimated Drug Discovery Platform
Seeking Alpha 13 Aug 2022

Biopharmaceutical Stocks Continue To Perform Well, With Many Attractive Values Remaining
Seeking Alpha 25 May 2021

Kronos: Recent IPO Developing Novel Oncology Therapies

Frequently Asked Questions (FAQ)

What's the price of Kronos Bio stock today?

One share of Kronos Bio stock can currently be purchased for approximately $0.88.
When is Kronos Bio's next earnings date?

Unfortunately, Kronos Bio's (KRON) next earnings date is currently unknown.
Does Kronos Bio pay dividends?

No, Kronos Bio does not pay dividends.
How much money does Kronos Bio make?

Kronos Bio has a market capitalization of 56.12M.
What is Kronos Bio's stock symbol?

Kronos Bio, Inc. is traded on the NASDAQ under the ticker symbol "KRON".
What is Kronos Bio's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Kronos Bio?

Shares of Kronos Bio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Kronos Bio's key executives?
Kronos Bio's management team includes the following people:
- Mr. Jorge F. DiMartino M.D., Ph.D. Chief Medical Officer & Executive Vice President of Clinical Devel.(age: 62, pay: $765,110)
- Dr. Norbert W. Bischofberger Ph.D. Pres, Chief Executive Officer & Director(age: 69, pay: $596,370)
- Dr. Yasir B. Al-Wakeel BCh, BM, MA Chief Financial Officer & Head of Corporation Devel.(age: 43, pay: $421,260)
- Mr. David M. Tanen J.D. Sec. & Director(age: 54, pay: $35,000)
- Mr. Joshua A. Kazam Co-Founder & Director(age: 48, pay: $35,000)
Is Kronos Bio founder-led company?

Yes, Kronos Bio is a company led by its founder Mr. Joshua A. Kazam.
How many employees does Kronos Bio have?

As Jul 2024, Kronos Bio employs 61 workers, which is 2% less then previous quarter.
When Kronos Bio went public?

Kronos Bio, Inc. is publicly traded company for more then 4 years since IPO on 9 Oct 2020.
What is Kronos Bio's official website?

The official website for Kronos Bio is kronosbio.com.
Where are Kronos Bio's headquarters?

Kronos Bio is headquartered at 1300 South El Camino Real, San Mateo, CA.
How can i contact Kronos Bio?

Kronos Bio's mailing address is 1300 South El Camino Real, San Mateo, CA and company can be reached via phone at +65 07815200.
What is Kronos Bio stock forecast & price target?

Based on 1 Wall Street analysts` predicted price targets for Kronos Bio in the last 12 months, the avarage price target is $1. The average price target represents a 13.63% change from the last price of $0.88.

Kronos Bio, Inc.

kronosbio.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.

+65 07815200

1300 South El Camino Real
San Mateo, CA 94402

CIK: 0001741830
ISIN: US50107A1043
CUSIP: 50107A104